TY - JOUR
T1 - Association of BNT162b2 SARS-CoV-2 vaccination during pregnancy with postnatal outcomes in premature infants
AU - Tamir-Hostovsky, Liran
AU - Maayan-Metzger, Ayala
AU - Gavri-Beker, Ayelet
AU - Watson, Douglas
AU - Leibovitch, Leah
AU - Strauss, Tzipi
N1 - Publisher Copyright:
© 2024 Foundation Acta Paediatrica. Published by John Wiley & Sons Ltd.
PY - 2024/10
Y1 - 2024/10
N2 - Aim: The effect of COVID-19 vaccine given during pregnancy on premature infants is unknown. This study aims to determine the association between maternal COVID-19 vaccine with postnatal outcome in premature infants. Methods: This is a single-centre retrospective case–control study of infants born before 35 weeks gestation to mothers who received SARS-CoV-2 vaccine during pregnancy compared with infant born to non-vaccinated mothers. Results: A total of 78 infants in each group were included. Infants in the vaccinated group had less respiratory distress syndrome (RDS) (p = 0.02) and less need for respiratory support (p = 0.002), and maternal vaccine had a protective effect on RDS [adjustable OR 0.38 (0.17–0.85)]. Vaccination during the first compared to the second trimester was associated with earlier gestational age (32.3 ± 2.1 vs. 33.3 ± 1.1 weeks, p = 0.03). Conclusion: We demonstrated that maternal SARS-CoV-2 vaccine is not associated with postnatal adverse effect in premature infants and potentially has a protective effect on RDS. Earlier gestational age among the infants born to mothers who received COVID-19 vaccine during the first trimester did not translate to higher rate of postnatal complications. These findings might suggest that COVID-19 vaccine is safe in high-risk pregnancies, but timing of administration should be considered. Further studies are needed to confirm our findings and the biological mechanism.
AB - Aim: The effect of COVID-19 vaccine given during pregnancy on premature infants is unknown. This study aims to determine the association between maternal COVID-19 vaccine with postnatal outcome in premature infants. Methods: This is a single-centre retrospective case–control study of infants born before 35 weeks gestation to mothers who received SARS-CoV-2 vaccine during pregnancy compared with infant born to non-vaccinated mothers. Results: A total of 78 infants in each group were included. Infants in the vaccinated group had less respiratory distress syndrome (RDS) (p = 0.02) and less need for respiratory support (p = 0.002), and maternal vaccine had a protective effect on RDS [adjustable OR 0.38 (0.17–0.85)]. Vaccination during the first compared to the second trimester was associated with earlier gestational age (32.3 ± 2.1 vs. 33.3 ± 1.1 weeks, p = 0.03). Conclusion: We demonstrated that maternal SARS-CoV-2 vaccine is not associated with postnatal adverse effect in premature infants and potentially has a protective effect on RDS. Earlier gestational age among the infants born to mothers who received COVID-19 vaccine during the first trimester did not translate to higher rate of postnatal complications. These findings might suggest that COVID-19 vaccine is safe in high-risk pregnancies, but timing of administration should be considered. Further studies are needed to confirm our findings and the biological mechanism.
KW - COVID-19 vaccine
KW - postnatal outcome
KW - prematurity
KW - respiratory distress syndrome
UR - http://www.scopus.com/inward/record.url?scp=85196746175&partnerID=8YFLogxK
U2 - 10.1111/apa.17329
DO - 10.1111/apa.17329
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 38923614
AN - SCOPUS:85196746175
SN - 0803-5253
VL - 113
SP - 2275
EP - 2281
JO - Acta Paediatrica, International Journal of Paediatrics
JF - Acta Paediatrica, International Journal of Paediatrics
IS - 10
ER -